Brief: Enlaza Therapeutics Strategic Collaboration With Vertex Pharmaceuticals To Develop War-Lock Drug Conjugates And T-Cell Engagers
02/09/2025 17:52
Sept 2 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: ENLAZA THERAPEUTICS: STRATEGIC COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP WAR-LOCK DRUG CONJUGATES AND T-CELL ENGAGERS ENLAZA: WILL RECEIVE $45 MILLION INCLUSIVE OF AN UPFRONT PAYMENT AND EQUITY INVESTMENT ENLAZA: FURTHER ELIGIBLE TO RECEIVE MORE THAN $2 BILLION IN FUTURE MILESTONE PAYMENTS ENLAZA: VERTEX WILL FUND ALL RESEARCH AND DEVELOPMENT COSTS RELATED TO FOUR-YEAR COLLABORATION Source text: ID:nBw3srhWfa Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31